1[1]Sablon E, Shapiro F, Zoulim F et al . Early detection of hepatitis B drug resistance: implications for patient management. Expert Rev Mol Diagn, 2003,3(5):535
2[2]Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology, 2001,120(4):1009
3[3]Hsu YS, Chien RN, Yeh CT et al . Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology, 2002,35(6):1522
4[4]Shimada N, Yamamoto K, Kuroda MJ et al . HBcAg-specific CD8 T cells play an important role in virus suppression, and acute flare-up is associated with the expansion of activated memory T cells. J Clin Immunol, 2003,23(3):223
5[5]Akuta N, Tsubota A, Suzuki F et al . Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis-an open-cohort study. J Hepatol, 2003,38(1):91
6[6]Tsubota A, Arase Y, Suzuki F et al . Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B. J Med Virol, 2004,73(1):7
7[7]Chien RN, Liaw YF. Short-term lamivudine therapy in patients with chronic hepatitis B. Intervirology, 2003,46(6):362
9[9]Tsai SL, Sheen IS, Chien RN et al . Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci, 2003,10(1):120
10[10]Perrillo RP, Lai CL, Liaw YF et al . Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. 2002,36(1):186
同被引文献11
1PERRILLO R P, LAI C L, LIAW Y F, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B [J]. Hepatology,2002, 36: 186.
2GUIDOTTI L G, CHISARI F V. Noncytolytic control of viral infections by the innate and adaptive immune response[J]. Annu Rev Immunol,2001, 19: 65.
3GUIDOTTI L G. The role af cytoto:dc T cells and cytokines in the control af hepatitis B virus infection[J]. Vaccine, 2002, 20(Suppl 4):A80.
4TSAI S L, LEE T H, CHIEN R N, et al. A method to increase tetrainer staining efficiency af CD8^+ T cells with MHC - peptide complexes: therapeutic applications in monitoring cytotoxic T lymphocyte activity during hepatitis B and C treatment[J]. J Immunol Methods, 2004,285: 71.
5CHEN G, SHANKAR P, LANGE C, et al. CD8 T cells specific for human immunodeficiency vires, Epstein - Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection[J]. Blood, 2001, 98: 156.
6KAKIMI K, ISOGAWA M, CHUNG J, et al. Immunogenicity and tolerogenicity af hepatitis B virus swactural and nonstractural proteins:implications for immunotherapy af persistent viral infections[J]. J Virol, 2002, 76: 8609.
7FERRARI C, MISSALE G, BONI C, et al. Immunopathogenesis of hepatitis B[J]. J Hepatol, 2003, 39(Suppl 1):S36.
8REIGNAT S, WEBSTER G J, BROWN D, et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection[J]. J Exp Med, 2002, 195: 1089.
9TSUBOTA A, ARASE Y, SUZUKI F, et al. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mtants in long- term lamivudine therapy for hepatitis B e antigen - positive chronic hepatitis B[J]. J Med Virol, 2004, 73: 7.
10MAINI M K, BONI C, LEE C K, et al. The role of virus - specific CD8^+ cells in liver damage and viral control during persistent hepatitis B virus infection[J]. J Exp Med, 2000, 191 : 1269.
